News - Page 9 of 13 - Leukaemia Care

9th April 2020

Support over the Easter Bank Holiday

Find out what support is available over the Easter Bank Holiday

9th March 2020

The Scottish Medicines Consortium (SMC) recommend the use of blinatumomab

The Scottish Medicines Consortium (SMC) have today recommended the use of blinatumomab for Philadelphia chromosome negative (Ph-ve), CD19 positive, B cell precursor acute lymphoblastic leukaemia (ALL), who have MRD of at least 0.1%.

26th February 2020

Over £180,000 raised from Telegraph Christmas Charity Appeal

For Christmas 2019, we were chosen by the Telegraph to be one of their Christmas appeal charities. We can now reveal how much was raised, and how this money will help those affected by blood cancer.

9th December 2019

The Scottish Medicine Consortium (SMC) recommends the use of ruxolitinib on the NHS for polycythaemia vera (PV) patients

The Scottish Medicine Consortium (SMC) has announced that it is recommending the use of ruxolitinib on the NHS for Polycythaemia vera (PV) patients who are resistant or intolerant to hydroxyurea. Ruxolitinib is not currently available for PV in England and Wales for the treatment of PV.

10th September 2019

SMC approves Kymriah CAR-T therapy for use on the NHS in Scotland for DLBCL patients

Yesterday, the Scottish Medicines Consortium approved the use of tisagenlecleucel-T (brand name Kymriah), on the NHS in Scotland, for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of CAR-T cell therapy.

13th August 2019

SMC approves venetoclax with rituximab for relapsed/refractory CLL patients in Scotland

The Scottish Medicine Consortium (SMC) has announced that it is recommending the use of venetoclax with rituximab on the NHS for chronic lymphocytic leukaemia (CLL) patients who have had at least one prior therapy. Read more about this decision in our article.

8th July 2019

Scottish Medicine Consortium (SMC) approve arsenic trioxide for NHS patients in Scotland.

The Scottish Medicines Consortium (SMC) have today announced that arsenic trioxide is recommended for NHS acute promyelocytic leukaemia (APL) patients in Scotland. Find out what this decision means for patients in our article.

21st June 2019

The National Institute of Health and Care Excellence (NICE) recommends the use of blinatumomab

The National Institute of Health and Care Excellence (NICE) have recommended the use of blinatumomab for Philadelphia chromosome negative (Ph-ve), CD19 positive, B cell precursor acute lymphoblastic leukaemia (ALL), who have MRD of at least 0.1%.

11th March 2019

Scottish Medicines Consortium has not approved the use of Tisagenlecleucel-T for diffuse large-B cell lymphoma (DLBCL)

Today, the Scottish Medicines Consortium (SMC) has not approved the use of Tisagenlecleucel-T (brand name Kymriah) on the NHS in Scotland for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of chimeric antigen receptor (CAR) T-cell therapy and is manufactured by Novartis.

11th March 2019

Liposomal cytarabine with daunorubicin approved for use in Scotland for t-AML and AML-MRC

The Scottish Medicines Consortium (SMC) has today recommended the use of liposomal cytarabine with daunorubicin to treat previously untreated therapy-related AML (t-AML) and AML with myelodysplastic changes (AML-MRC).